NCT03921554 - JAK Inhibitor Treatment in AGS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

January 4, 2024

Study Completion Date

March 25, 2024

Conditions

Aicardi Goutieres Syndrome

Interventions

DRUG

Baricitinib

Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.

Trial Locations (1)

19104

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Adeline Vanderver, MD

OTHER